Dual selective PI3K delta and gamma inhibitors and / or salt-inducible kinase 3 inhibitors for treatment of solid tumors

By using a combination of dual-selective PI3Kδ and gamma inhibitors and SIK3 inhibitors, the problem of limited efficacy of existing breast cancer treatment methods after resistance is solved, and the therapeutic effect on breast cancer and other solid tumors is significantly improved. Especially the efficacy in TNBC.

CN119095599APending Publication Date: 2024-12-06RHIZEN PHARM SA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380036822.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-29
Filing Date
2023-04-27
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing breast cancer treatments still have challenges in terms of treatment, side effects and the clinical benefits expected by patients, especially after resistance to hormone therapy, where chemotherapy is the only standard treatment option, but its effect is limited, especially It is in triple-negative breast cancer (TNBC).

Method used

Dual-selective PI3Kδ and gamma inhibitors, salt-inducible kinase 3 (SIK3) inhibitors or combinations thereof are used as pharmaceutical compositions for the treatment of solid tumors such as breast cancer, ovarian cancer, pancreatic cancer, etc., and are administered or other channels. To enhance anti-tumor activity.

Benefits of technology

It significantly improves the therapeutic effect on solid tumors such as breast cancer, ovarian cancer and pancreatic cancer, especially in hormone receptor-positive and HER2-negative breast cancer and triple-negative breast cancer (TNBC), and enhances the anti-cancer effect on a variety of The sensitivity of the drug extends the patient's survival.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119095599A_ABST
    Figure CN119095599A_ABST
Patent Text Reader

Abstract

The present invention relates to the use of dual selective PI3K [delta] and [gamma] (PI3K [delta] / [gamma]) inhibitors, salt-induced kinase 3 (SIK3) inhibitors, or combinations thereof, and pharmaceutical compositions comprising them for the treatment of solid tumors such as breast cancer. The present invention also relates to compounds of formula (A) (also referred to as terralissemia, terralissemia) for use in the treatment of solid tumors such as breast cancer, (S)-2-(1-(9H-purin-6-ylamino) propyl)-3-(3-fluorophenyl)-4H-chromen-4-one), dual selective PI3K delta and gamma (PI3K delta / gamma) inhibitors or pharmaceutically acceptable salts thereof or compounds of formula (M) ((S)-3-(3-fluorophenyl)-2-(1-((8-hydroxy-9H-purin-6-ylamino) propyl)-4H-chromen-4-one), salt-inducible kinase 3 (SIK3) An inhibitor or a pharmaceutically acceptable salt thereof, or a combination thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Compositions and methods for treating solid tumors

[0002] This application claims the benefit of Indian Patent Application No. 202241025286 filed on April 29, 2022, which is hereby incorporated by reference in its entirety. Technical Field

[0003] The present invention relates to dual selective PI3Kδ and γ (PI3Kδ / γ) inhibitors, salt-inducible kinase 3 (SIK3) inhibitors or combinations thereof, and pharmaceutical compositions comprising them for use in treating solid tumors such as, for example, breast cancer, ovarian cancer, pancreatic cancer and colon cancer. Background Art

[0004] Solid tumors are abnormal masses of tissue that usually do not contain cysts or areas of fluid. Solid tumors may be benign (noncancerous) or malignant (cancerous). Different types of solid tumors are named after the types of cells that form them. Examples of solid tumors include sarcomas and carcinomas. The word tumor does not always mean cancer. When discussing malignant (cancerous) tumors, the different kinds of cancerous solid tumors are named after the types of cells that make them up:

[0005] ● Sarcoma—cancer that arises from connective or supporting tissue, such as bone or muscle.

[0006] ●Carcinoma – Cancers that arise from glandular and epithelial cells of the body that are present in the skin and tissues that cover or line the body’s organs.

[0007] Breast cancer is the most common form of cancer in women and the second most common cause of cancer-related death in women. Breast cancer accounts for 22% of all female cancers and 15% of female cancer deaths.

[0008] Breast cancer is a cancer that develops due to uncontrolled changes in the function or growth of the cells that form the breast tissue. These changes transform these cells into cancer cells that have the ability to spread. Breast cancer can occur in both men and women, but it is more common in women. Risk factors for breast cancer include obesity, lack of physical exercise, alcoholism, hormone replacement therapy during menopause, ionizing radiation, early age at menarche, late childbearing or no childbearing, older age, a previous history of breast cancer, and a family history of breast cancer.

[0009] Breast cancer can spread when cancer cells enter the blood or lymph system and are then carried to other parts of the body. If cancer cells have spread to your lymph nodes, there is a good chance that these cells have traveled through the lymph system and spread (metastasized) to other parts of your body. However, not all women with cancer cells in their lymph nodes will develop metastases, and some women who do not have cancer cells in their lymph nodes may develop metastases later. Breast cancer develops because of gene mutations or damage to your DNA. These may be related to exposure to estrogen, inherited gene defects, or inherited genes that can cause cancer (such as the BRCA1 and BRCA2 genes).

[0010] Types of breast cancer include:

[0011] ● Ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS) are the most common types of non-invasive breast cancer. It starts in the milk ducts / lobules of the breast and is non-invasive because it has not spread to any surrounding breast tissue. DCIS and LCIS are not life-threatening.

[0012] However, DCIS and LCIS may increase the risk of developing invasive breast cancer in the future.

[0013] Invasive ductal carcinoma (IDC) is the most common type, and invasive lobular carcinoma (ILC) is the second most common type of breast cancer. About 80% of all breast cancers are invasive ductal carcinomas. Invasive ductal carcinoma / invasive lobular carcinoma means that the cancer that started in the milk ducts / lobules of the breast has broken through the lining of the ducts / lobules and spread into the surrounding breast tissue. Over time, invasive ductal / lobular breast cancer can spread to the lymph nodes and possibly to other parts of the body.

[0014] Paget's disease of the nipple is a rare type of breast cancer in which cancer cells grow in the nipple or areola (the area around the nipple). The nipple and areola often become scaly, red, itchy, and inflamed. Many people with Paget's disease also have DCIS, or invasive breast cancer, elsewhere in the breast. Abnormal changes in the nipple and areola are often the first sign that breast cancer is present.

[0015] Inflammatory breast cancer is a rare and aggressive type of breast cancer that affects the blood vessels in the skin and / or the lymph vessels in the breast. This causes the breast to become red and inflamed.

[0016] ●Phyllodactyl tumors of the breast are rare. Although most phyllodes tumors are benign (not cancerous), some are malignant (cancerous). Phyllodes tumors tend to grow quickly, but they rarely spread outside the breast. Phyllodes tumors develop in the connective tissue or stroma (the tissue that holds everything in the breast together), outside the ducts and lobules of the breast.

[0017] Metastatic breast cancer (MBC) is breast cancer that has spread beyond the breast to other organs in the body (most commonly the bones, lungs, liver, or less commonly the brain). Metastatic breast cancer is usually discovered through symptoms, which may be recurring pain or cough, shortness of breath, loss of appetite, headaches, or injuries. It may also be possible to diagnose metastases through routine scans. Metastatic breast cancer is incurable, with a 5-year survival rate of 28%.

[0018] In the United States, more than 42,000 patients die from MBC each year.

[0019] Breast cancer is the most common type of cancer in women worldwide (Bray et al., CA Cancer J. Clin., 68, 394–424, 2018, doi: 10.3322 / caac.21492). Breast cancer is generally divided into three subtypes, and targeted therapies are determined by the subtype. Hormone receptor positive (HR+) / HER2- is the most common subtype and accounts for about 70% of breast cancer patients (Howlader et al., J. Natl. Cancer Inst., 106, 2014: dju055). Treatment usually includes endocrine therapy (ET) (Waks et al., J. Am. Med. Assoc., 321, 288-300, 2019). The approval of CDK4 / 6 inhibitors in combination with ET has greatly improved survival outcomes (Shah et al., Oncology, 32, 216–222, 2018). However, after resistance to hormone therapy, chemotherapy becomes the only standard treatment option (Cardoso et al., J. Natl. Cancer Inst., 101, 1174-1181, 2009, doi: 10.1093 / jnci / djp235). 15% to 20% of patients are diagnosed as HER2+ (Howlader et al., J. Natl. Cancer Inst., 106, 2014, doi: dju055). Standard care treatment for HER2+ breast cancer includes HER2-targeted antibodies and chemotherapy (Romond et al., N. Engl. J. Med., 353, 1673-1684, 2005; Waks et al., J. Am. Med. Assoc., 321, 288-300, 2019). However, even if the disease progresses during therapy, continued administration of anti-HER2 and chemotherapy remains a follow-up treatment (Olson et al., Ann. Oncol., 23, 93-97, 2012, doi: 10.1093 / annonc / mdr061). Accounting for 10% to 20% of newly diagnosed breast cancer cases, triple-negative breast cancer (TNBC) is characterized by lack of hormone receptor expression and lack of HER2 / NEU gene overexpression (Dent et al., Clin. Cancer Res., 13, 4429-4434, 2007, doi: 10.1158 / 1078-0432.ccr-06-3045). TNBC displays high heterogeneity in mutational profiles and shows the highest risk of relapse (Dent et al., Clin. Cancer Res., 13, 4429-4434, 2007, doi: 10.1158 / 1078-0432.ccr-06-3045).Due to the lack of targets, chemotherapy is currently the main treatment for TNBC, but clinical benefits are usually not durable due to frequent acquired resistance (Liedtke et al., J. Clin. Oncol., 26, 1275-1281, 2008, doi: 10.1200 / jco.2007.14.4147).

[0020] Upregulation of the phosphoinositide 3-kinase (PI3K) signaling pathway is commonly observed in breast cancer patients. It is associated with the development of breast cancer tumor development, progression, and resistance to hormone therapy and chemotherapy (Guerrero-Zotano et al., Cancer Metastasis Rev., 35, 515–524, 2016, doi: 10.1007 / s10555-016-9637-x; Drullinsky et al., Breast Cancer Res. Treatment, 181, 233–248 (2020). doi: 10.1007 / s10549-020-05618-1). Therefore, it is necessary to elucidate the mechanism of the PI3K signaling pathway in breast cancer and explore the potential of PI3K inhibitors alone or in combination with other therapies in the treatment of different subtypes of breast cancer in both early and metastatic settings.

[0021] Pathological activation of the PI3K pathway is one of the most common signaling events associated with cell transformation, cancer formation and metastasis in solid tumors (Okkenhaug et al., Cancer Discovery, 6 (10), 1090-1105, 2016). This situation is illustrated by frequent activating mutations in PIK3CA and loss of PTEN (phosphatase and tensin homolog) function in common cancers such as breast cancer, colon cancer and ovarian cancer. PIK3CD is mostly non-mutated in cancer, but the expression level of p110δ protein seems to act as an intrinsic oncogenic driver in various solid tumors (including breast, prostate, colorectal, liver, Merkel cell carcinoma, glioblastoma and neuroblastoma). (Lydia Xenou et al., Clin. Sci. (Lond.), 134 (12), 1377–1397, 2020). Recent studies have shown that the oncogenic potential of overexpressed p110δPI3K is associated with suppressed PTEN lipid phosphatase activity in cancer cells. Given that PTEN somatic mutations occur in a small fraction of human breast cancers and that p110δ is highly expressed in this tumor type, PI3Kδ inhibitors may offer an opportunity to intervene in breast cancer (Tzenaki et al., The FASEB Journal, 26(6), 2498-2508, 2012). Recently, p110δ selective inhibitors are being investigated as potential single agent therapies or combination therapies to improve responses in patients with solid tumors.

[0022] The immunosuppressive microenvironment in tumor tissue is partially mediated by non-tumor stromal cells, most notably tumor-associated macrophages (TAM) (Ge Z, Ding S., Front Oncol., 10, 590941, 2020). Data show that PI3Kγ, as a molecular switch, turns on immunosuppression while turning off immunostimulatory activity. Therefore, PI3Kγ inhibitors can cause shift / reprogramming, leading to enhanced adaptive immunity, including increased recruitment and cytotoxicity of T cells. This change in the immune environment significantly reduces tumor growth and metastasis (Kaneda, et al., Nature, 539 (7629), 437-442, 2016).

[0023] Salt-inducible kinases (SIKs) are highly conserved serine / threonine protein kinases that belong to the AMP-activated protein kinase (AMPK) family and play a role in steroidogenesis, lipogenesis, and tumor regulation. SIKs are dysregulated in various cancers, including ovarian, breast, prostate, and lung cancers, suggesting that SIKs may play a role in tumorigenesis or progression. SIK3 promotes tumor cell resistance to cytotoxic T-cell attack by switching TNF signaling from apoptosis to survival. SIK3-specific inhibitors alone sensitize multiple human and murine cancer cell lines to TNF-induced apoptosis by engaging the HDAC4 / NFkB pathway. Therefore, targeting SIK3 to resensitize tumors to immune attack is a compelling therapeutic strategy for cancer treatment.

[0024] SIK3 is highly expressed in about 55% of breast cancer patients and significantly controls the G1 / S process by upregulating the gene expression of cyclin D and cyclin E, while downregulating the expression of p21 and p27, or increasing the activity of cyclin-dependent kinase 2 (CDK2). SIK3 deficiency leads to prolonged mitosis in mice and human cells, thereby increasing the sensitivity of cancer cells to a variety of anti-mitotic drugs. Studies have also shown that SIK3 expression is upregulated in breast cancer, promoting aerobic glycolysis and tumor growth by activating the mTOR / Akt signaling pathway. SIK3 also plays an active role in mediating the high-salt-induced inflammatory signaling response that leads to cancer cell proliferation. SIK3 induces the upregulation of inflammatory arginine metabolic factors such as iNOS and ass-1 and the downregulation of anti-inflammatory enzymes such as arginase-1 and ornithine decarboxylase in breast cancer.

[0025] Although some progress has been made in the treatment of breast cancer, there are still challenges in treatment, side effects and clinical benefits expected by patients. Therefore, there is still an unmet need for drugs to treat solid tumors (such as, for example, breast cancer). Summary of the invention

[0026] The present inventors surprisingly found that dual selective PI3Kδ and γ (PI3Kδ / γ) inhibitors, salt-inducible kinase 3 (SIK3) inhibitors or combinations thereof, optionally in combination with other drugs, show excellent activity against solid tumors, such as, for example, pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, kidney cancer, hepatocellular carcinoma, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain tumors, bone cancer and soft tissue sarcoma, and more importantly, colon cancer, ovarian cancer, pancreatic cancer and breast cancer, such as, for example, metastatic breast cancer, hormone receptor (HR)-positive and HER2-negative breast cancer and triple-negative breast cancer (TNBC).

[0027] Thus, in one aspect, the present invention relates to (i) a compound of formula (A) (also known as tenalicept, (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one), a dual selective PI3Kδ and γ (PI3Kδ / γ) inhibitor or a pharmaceutically acceptable salt thereof, (ii) a compound of formula (M) ((S)-3-(3-fluorophenyl)-2-(1-((8-hydroxy-9H-purin-6-yl)amino)propyl)-4H-chromen-4-one), a salt-inducible kinase 3 (SIK3) inhibitor or a pharmaceutically acceptable salt thereof, or (iii) a combination thereof for use in the treatment of solid tumors (such as, for example, breast cancer, colon cancer, ovarian cancer and pancreatic cancer).

[0028] Another embodiment is a pharmaceutical composition comprising (i) a dual selective PI3Kδ and γ (PI3Kδ / γ) inhibitor and (ii) a salt-inducible kinase 3 (SIK3) inhibitor.

[0029] Another embodiment is a pharmaceutical composition for treating solid tumors such as, for example, breast cancer, colon cancer, ovarian cancer and pancreatic cancer, comprising (i) a compound of formula (A) or a pharmaceutically acceptable salt thereof, (ii) a compound of formula (M) or a pharmaceutically acceptable salt thereof, or (iii) a combination thereof.

[0030] The compound of formula (M) is the major metabolite of the compound of formula (A) in the human body.

[0031] The structures of the compound of formula (A) and the compound of formula (M) are shown below.

[0032]

[0033] Compounds of formula (A) (also referred to herein as Compound A) and their preparation are disclosed in International Publication No. WO 14 / 195888, which is hereby incorporated by reference in its entirety. Compounds of formula (M) (also referred to herein as Compound M) and their preparation are disclosed in International Publication No. WO 21 / 229452, which is hereby incorporated by reference in its entirety.

[0034] In another aspect, the present invention relates to a method of treating solid tumors (such as breast cancer), comprising administering to a subject (e.g., a human subject in need thereof) a dual selective PI3Kδ and γ (PI3Kδ / γ) inhibitor, a salt-inducible kinase 3 (SIK3) inhibitor, or a combination thereof.

[0035] Another aspect is the use of a dual selective PI3Kδ and γ (PI3Kδ / γ) inhibitor, a salt-inducible kinase 3 (SIK3) inhibitor, or a combination thereof for treating a solid tumor (such as breast cancer, ovarian cancer, pancreatic cancer, or colon cancer) in a subject (such as a human subject in need thereof).

[0036] In certain embodiments of any of the methods and uses described herein, the solid tumor is selected from a carcinoma, a sarcoma, or any combination thereof.

[0037] In certain embodiments of any of the methods and uses described herein, the solid tumor is selected from pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular carcinoma, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain tumor, bone cancer, and soft tissue sarcoma.

[0038] In certain embodiments of any of the methods and uses described herein, the solid tumor is selected from non-small cell lung cancer, small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, and breast cancer.

[0039] In certain embodiments of any of the methods and uses described herein, the solid tumor is selected from breast cancer, colon cancer, ovarian cancer, and pancreatic cancer.

[0040] In certain embodiments of any of the methods and uses described herein, the solid tumor is ovarian cancer.

[0041] In certain embodiments of any of the methods and uses described herein, the solid tumor is pancreatic cancer.

[0042] In certain embodiments of any of the methods and uses described herein, the solid tumor is colon cancer.

[0043] In certain embodiments of any of the methods and uses described herein, the solid tumor is breast cancer.

[0044] In certain embodiments of any of the methods and uses described herein, the breast cancer is selected from invasive breast cancer, non-invasive breast cancer, phyllodes tumor of the breast, locally advanced or metastatic breast cancer, hormone receptor (HR) positive and HER2 negative breast cancer, hormone receptor (HR) positive and HER2 positive breast cancer, hormone receptor (HR) negative and HER2 positive breast cancer, hormone receptor (HR) negative and HER2 negative breast cancer (triple negative breast cancer - TNBC).

[0045] In certain embodiments of any of the methods and uses described herein, the breast cancer is selected from invasive breast cancer, non-invasive breast cancer, and cancerous phyllodes tumor of the breast.

[0046] In certain embodiments of any of the methods and uses described herein, the breast cancer is selected from locally advanced or metastatic breast cancer.

[0047] In certain embodiments of any of the methods and uses described herein, the breast cancer is selected from hormone receptor (HR) positive and HER2 negative breast cancer, hormone receptor (HR) positive and HER2 positive breast cancer, hormone receptor (HR) negative and HER2 positive breast cancer, and hormone receptor (HR) negative and HER2 negative breast cancer (triple negative breast cancer - TNBC).

[0048] In certain embodiments of any of the methods and uses described herein, the breast cancer is hormone receptor (HR) positive and HER2 negative breast cancer.

[0049] In certain embodiments of any of the methods and uses described herein, the breast cancer is triple-negative breast cancer.

[0050] In certain embodiments of any of the methods and uses described herein, the breast cancer is selected from metastatic breast cancer, hormone receptor (HR) positive and HER2 negative breast cancer, and triple negative breast cancer (TNBC).

[0051] On the other hand, the present invention relates to a method for treating solid cancers (e.g., breast cancer, ovarian cancer, pancreatic cancer, colon cancer), which comprises administering to a subject (e.g., a human subject in need thereof) a dual selective PI3Kδ and γ (PI3Kδ / γ) inhibitor or a pharmaceutical composition comprising a dual selective PI3Kδ and γ (PI3Kδ / γ) inhibitor.

[0052] In certain embodiments of any of the methods and uses described herein, the dual selective PI3Kδ and γ inhibitor is a compound of formula (A) or a pharmaceutically acceptable salt thereof.

[0053] Another aspect of the present invention is the use of a compound of formula (A) or a pharmaceutically acceptable salt thereof, a compound of formula (M) or a pharmaceutically acceptable salt thereof, or a combination thereof in the preparation of a medicament for treating solid tumors.

[0054] In certain embodiments of any of the methods and uses described herein, the subject is a human.

[0055] In certain embodiments of any of the methods and uses described herein, the compound of formula (A) or a pharmaceutically acceptable salt thereof, the compound of formula (M) or a pharmaceutically acceptable salt thereof, or a combination thereof is administered by oral route, intravenous route, intramuscular injection route or intraperitoneal injection route. In humans, the conventional route of administration is the oral route.

[0056] In certain embodiments of any of the methods and uses described herein, a compound of formula (A) or a pharmaceutically acceptable salt thereof, a compound of formula (M) or a pharmaceutically acceptable salt thereof, or a combination thereof is used to prepare a medicament for treating breast cancer administered by the oral route.

[0057] Another aspect of the present invention is a method for inhibiting dual PI3Kδ and γ kinases in a breast cancer patient, the method comprising administering to the patient an effective amount of a compound of formula (A) or a pharmaceutically acceptable salt thereof, a compound of formula (M) or a pharmaceutically acceptable salt thereof, or a combination thereof.

[0058] On the other hand, the present invention also provides a method for treating solid tumors in a subject (e.g., a human subject in need thereof), the method comprising administering to the subject a compound of formula (A) or a pharmaceutically acceptable salt thereof, a compound of formula (M) or a pharmaceutically acceptable salt thereof, or a combination thereof.

[0059] In another aspect, the present invention relates to a pharmaceutical composition for treating solid tumors, comprising a compound of formula (A) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

[0060] In another aspect, the present invention relates to a pharmaceutical composition for treating solid tumors, comprising a compound of formula (M) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

[0061] In certain embodiments of any of the methods and uses described herein, a compound of Formula (A) or a pharmaceutically acceptable salt thereof is administered for first-line treatment of breast cancer and / or treatment of unresectable breast cancer.

[0062] In certain embodiments of any of the methods and uses described herein, a compound of Formula (A) or a pharmaceutically acceptable salt thereof is administered for treating a human subject having recurrent breast cancer, refractory breast cancer, or recurrent-refractory breast cancer.

[0063] In certain embodiments of any of the methods and uses described herein, the dual selective PI3Kδ and γ (PI3Kδ / γ) inhibitor and / or salt-inducible kinase 3 (SIK3) inhibitor is administered orally.

[0064] In certain embodiments of any of the methods and uses described herein, the compound of formula (A) or a pharmaceutically acceptable salt thereof is administered orally.

[0065] In certain embodiments of any of the methods and uses described herein, the compound of formula (A), or a pharmaceutically acceptable salt thereof, is administered (e.g., orally) in a dosage range of about 25 mg / day to about 2400 mg / day, such as about 50 mg / day to about 2000 mg / day, about 100 mg / day to about 1600 mg / day, about 200 mg / day to about 1200 mg / day, or about 400 mg / day to about 800 mg / day.

[0066] In certain embodiments of any of the methods and uses described herein, the compound of Formula (A) or a pharmaceutically acceptable salt thereof is administered (e.g., orally) in a dosage range of about 200 mg to about 1200 mg twice a day (i.e., about 400 mg to 2400 mg total per day) or about 400 mg to about 800 mg twice a day (i.e., about 800 mg to 1600 mg total per day).

[0067] In certain embodiments of any of the methods and uses described herein, the compound of Formula (A) or a pharmaceutically acceptable salt thereof is administered orally in a single dose or divided doses (e.g., two, three, or four doses per day) (e.g., orally).

[0068] In other embodiments of any of the methods and uses described herein, a compound of formula (A) or a pharmaceutically acceptable salt thereof is used in combination (administered together or sequentially) with an anti-cancer therapy, endocrine therapy, one or more cytostatic, cytotoxic or anti-cancer agents, targeted therapy, or any combination of any of the foregoing.

[0069] In one embodiment of any of the pharmaceutical compositions described herein, the pharmaceutical composition further comprises one or more cytostatic, cytotoxic and / or anti-cancer agents.

[0070] In another aspect, the invention relates to a method of treating a solid cancer (eg, breast cancer), the method comprising administering to a subject (eg, a human subject in need thereof) a salt-inducible kinase 3 (SIK3) inhibitor.

[0071] In additional embodiments of any of the methods and uses described herein, the SIK-3 inhibitor is a compound of formula (M) or a pharmaceutically acceptable salt thereof.

[0072] In another aspect, the present invention relates to use of a compound of formula (M) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating breast cancer.

[0073] In certain embodiments of any of the methods and uses described herein, the subject is a human.

[0074] In certain embodiments of any of the methods and uses described herein, the compound of formula (M) or a pharmaceutically acceptable salt thereof is administered by an oral route, an intravenous injection route, an intramuscular injection route, or an intraperitoneal injection route.

[0075] Another aspect of the present invention is the use of a compound of formula (M) or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of breast cancer administered by the oral route.

[0076] Another aspect of the invention is a method of inhibiting salt-inducible kinase 3 (SIK3) in a breast cancer patient (eg, a human breast cancer patient), the method comprising administering to the patient an effective amount of a compound of formula (M) or a pharmaceutically acceptable salt thereof.

[0077] The present invention also provides a method of treating breast cancer in a subject (eg, a human subject in need thereof), the method comprising administering to the subject a compound of formula (M) or a pharmaceutically acceptable salt thereof.

[0078] In another aspect, the present invention relates to a pharmaceutical composition for treating breast cancer, comprising a compound of formula (M) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

[0079] In additional embodiments of any of the methods and uses described herein, the compound of formula (M) or a pharmaceutically acceptable salt thereof is administered for first-line treatment of breast cancer and / or treatment of unresectable breast cancer.

[0080] In additional embodiments of any of the methods and uses described herein, a compound of Formula (M) or a pharmaceutically acceptable salt thereof is administered (e.g., orally) for treating a human subject having recurrent breast cancer, refractory breast cancer, or recurrent-refractory breast cancer.

[0081] In additional embodiments of any of the methods and uses described herein, the compound of formula (M) or a pharmaceutically acceptable salt thereof is administered orally.

[0082] In additional embodiments of any of the methods and uses described herein, the compound of formula (M), or a pharmaceutically acceptable salt thereof, is administered (e.g., orally) in a dosage range of about 25 mg / day to about 2400 mg / day, such as about 50 mg / day to about 2000 mg / day, about 100 mg / day to about 1600 mg / day, about 200 mg / day to about 1200 mg / day, or about 400 mg / day to about 800 mg / day.

[0083] In additional embodiments of any of the methods and uses described herein, the compound of Formula (M) or a pharmaceutically acceptable salt thereof is administered (e.g., orally) in a dosage range of about 200 mg to about 1200 mg twice a day (i.e., about 400 mg to 2400 mg total per day) or about 400 mg to about 800 mg twice a day (i.e., about 800 mg to 1600 mg total per day).

[0084] In additional embodiments of any of the methods and uses described herein, the compound of Formula (M) or a pharmaceutically acceptable salt thereof is orally administered in a single dose or in divided doses (eg, two, three, or four doses per day).

[0085] In other embodiments of any of the methods and uses described herein, a compound of formula (M), or a pharmaceutically acceptable salt thereof, is used in combination (administered together or sequentially) with an anti-cancer therapy, an endocrine therapy, one or more cytostatic, cytotoxic or anti-cancer agents, a targeted therapy, or any combination of any of the foregoing.

[0086] In one embodiment of any of the pharmaceutical compositions described herein, the pharmaceutical composition further comprises one or more cytostatic agents, cytotoxic agents and / or anti-cancer agents or any combination of any of the foregoing.

[0087] Another aspect of the invention is a method of inhibiting SIK3 in a breast cancer patient, the method comprising administering to the patient an effective amount of a SIK3 compound according to any of the embodiments described herein.

[0088] In another aspect, the invention relates to a method of treating solid cancer (e.g., breast cancer) in a subject (e.g., a subject in need thereof), the method comprising administering to the subject a dual selective PI3Kδ and γ (PI3Kδ / γ) inhibitor and a salt-inducible kinase 3 (SIK3) inhibitor.

[0089] In one embodiment of any of the methods and uses described herein, the dual selective PI3Kδ and γ inhibitor is a compound of formula (A) or a pharmaceutically acceptable salt thereof, and the SIK-3 inhibitor is a compound of formula (M) or a pharmaceutically acceptable salt thereof.

[0090] In another aspect, the present invention relates to the use of a combination of a compound of formula (A) or a pharmaceutically acceptable salt thereof and a compound of formula (M) or a pharmaceutically acceptable salt thereof for preparing a medicament for treating breast cancer.

[0091] In one embodiment of any of the methods and uses described herein, the compound of formula (A) or a pharmaceutically acceptable salt thereof and the compound of formula (M) or a pharmaceutically acceptable salt thereof are administered orally, intravenously, intramuscularly or intraperitoneally.

[0092] In one embodiment of any of the methods and uses described herein the compound of formula (A) or a pharmaceutically acceptable salt thereof and the compound of formula (M) or a pharmaceutically acceptable salt thereof are administered by the oral route.

[0093] On the other hand, the present invention relates to the use of a combination of a compound of formula (A) or a pharmaceutically acceptable salt thereof and a compound of formula (M) or a pharmaceutically acceptable salt thereof for preparing a medicament for treating breast cancer, wherein the compound of formula (A) or a pharmaceutically acceptable salt thereof and the compound of formula (M) or a pharmaceutically acceptable salt thereof are administered via the oral route.

[0094] The present invention also relates to a method for treating breast cancer in a subject (e.g., a subject in need thereof), the method comprising administering a dual selective PI3Kδ and γ inhibitor compound of formula (A) or a pharmaceutically acceptable salt thereof, in combination with a SIK3 inhibitor compound of formula (M) or a pharmaceutically acceptable salt thereof.

[0095] The present invention further relates to a pharmaceutical composition (e.g., a pharmaceutical composition for treating solid tumors such as breast cancer, comprising a compound of formula (A) or a pharmaceutically acceptable salt thereof, in combination with a compound of formula (M) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0096] In additional embodiments of any of the methods and uses described herein, a combination of a compound of formula (A) or a pharmaceutically acceptable salt thereof and a compound of formula (M) or a pharmaceutically acceptable salt thereof is administered for first-line treatment of breast cancer and / or treatment of unresectable breast cancer.

[0097] In additional embodiments of any of the methods and uses described herein, a compound of formula (A) or a pharmaceutically acceptable salt thereof and a compound of formula (M) or a pharmaceutically acceptable salt thereof are administered for treating a human subject having recurrent breast cancer, refractory breast cancer and / or recurrent-refractory breast cancer.

[0098] In additional embodiments of any of the methods and uses described herein, the combination of a compound of formula (A), or a pharmaceutically acceptable salt thereof, and a compound of formula (M), or a pharmaceutically acceptable salt thereof, is administered orally.

[0099] In additional embodiments of any of the methods and uses described herein, the combination of a compound of formula (A), or a pharmaceutically acceptable salt thereof, and a compound of formula (M), or a pharmaceutically acceptable salt thereof, is administered (e.g., orally) in a dosage range of about 25 mg / day to about 2400 mg / day, such as about 50 mg / day to about 2000 mg / day, about 100 mg / day to about 1600 mg / day, about 200 mg / day to about 1200 mg / day, or about 400 mg / day to about 800 mg / day.

[0100] In additional embodiments of any of the methods and uses described herein, a combination of a compound of Formula (A) or a pharmaceutically acceptable salt thereof and a compound of Formula (M) or a pharmaceutically acceptable salt thereof is administered to the subject (e.g., orally) at a dose of about 25 mg to about 2400 mg, about 25 mg to about 2000 mg, about 25 mg to about 1800 mg, about 25 mg to about 1600 mg, about 25 mg to about 1200 mg, about 25 mg to about 1000 mg, about 25 mg to about 800 mg, about 25 mg to about 600 mg, about 25 mg to about 400 mg, or about 25 mg to 200 mg.

[0101] In additional embodiments of any of the methods and uses described herein, a combination of a compound of Formula (A) or a pharmaceutically acceptable salt thereof and a compound of Formula (M) or a pharmaceutically acceptable salt thereof is administered to the subject (e.g., orally) at a dose of about 100 mg to about 2400 mg, about 100 mg to about 2000 mg, about 100 mg to about 1800 mg, about 100 mg to about 1600 mg, about 100 mg to about 1200 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, or about 100 mg to about 200 mg.

[0102] In additional embodiments of any of the methods and uses described herein, the combination of a compound of formula (A), or a pharmaceutically acceptable salt thereof, and a compound of formula (M), or a pharmaceutically acceptable salt thereof, is administered (e.g., orally) in a dosage range of about 200 mg to about 1200 mg twice a day (i.e., about 400 mg to 2400 mg total per day) or about 400 mg to about 800 mg twice a day (i.e., about 800 mg to 1600 mg total per day).

[0103] In additional embodiments of any of the methods and uses described herein, the combination of a compound of formula (A) or a pharmaceutically acceptable salt thereof and a compound of formula (M) or a pharmaceutically acceptable salt thereof are each administered independently in a single dose or in divided doses.

[0104] In another aspect, the present invention relates to a method of treating breast cancer in a subject (e.g., a human subject in need thereof), the method comprising administering to the subject a combination of a compound of formula (A) or a pharmaceutically acceptable salt thereof and a compound of formula (M) or a pharmaceutically acceptable salt thereof, in combination with anti-cancer therapy, endocrine therapy, one or more cytostatic agents, cytotoxic agents or anti-cancer agents, targeted therapy, or any combination of any of the foregoing (administered together or sequentially).

[0105] In yet another aspect, the invention relates to a method of treating breast cancer in a subject (e.g., a human subject in need thereof), the method comprising administering to the subject a combination of a compound of formula (A) or a pharmaceutically acceptable salt thereof and a compound of formula (M) or a pharmaceutically acceptable salt thereof, in combination with one or more cytostatic agents, cytotoxic agents or anticancer agents, or any combination of any of the foregoing (administered together or sequentially).

[0106] In another aspect, the invention relates to a method of treating breast cancer in a subject (e.g., a subject in need thereof), the method comprising administering to the subject a combination of a compound of formula (A) or a pharmaceutically acceptable salt thereof and a compound of formula (M) or a pharmaceutically acceptable salt thereof, in combination with one or more anti-cancer therapies, one or more cytostatic, cytotoxic or anti-cancer agents, targeted therapies, or any combination of any of the foregoing (administered together or sequentially).

[0107] In another aspect, the invention relates to a method of treating a solid cancer in a subject (e.g., a human subject in need thereof), the method comprising administering to the subject a combination of a compound of formula (A) or a pharmaceutically acceptable salt thereof and a compound of formula (M) or a pharmaceutically acceptable salt thereof, in combination with one or more anticancer agents, one or more cytostatic agents or cytotoxic agents (administered together or sequentially).

[0108] In another aspect, the invention relates to a method of treating a solid cancer in a subject (e.g., a human subject in need thereof), the method comprising administering to the subject a combination of a compound of formula (A) or a pharmaceutically acceptable salt thereof and a compound of formula (M) or a pharmaceutically acceptable salt thereof, in combination with one or more anticancer agents, one or more cytostatic or cytotoxic agents, or any combination of any of the foregoing (administered together or sequentially), such as, for example, one or more PARP inhibitors, CDK inhibitors, MEK inhibitors, B-RAF inhibitors, m-TOR inhibitors, selective estrogen receptor degraders (SERDs), HER-2 or EGFR inhibitors or dual inhibitors, PD1 inhibitors, RET inhibitors, or any combination of any of the foregoing.

[0109] In another aspect, the invention relates to a method of treating a solid cancer in a subject (e.g., a human subject in need thereof), the method comprising administering to the subject a combination of a compound of formula (A) or a pharmaceutically acceptable salt thereof and a compound of formula (M) or a pharmaceutically acceptable salt thereof, in combination with one or more anticancer agents, one or more cytostatic or cytotoxic agents, or any combination of any of the foregoing (such as, for example, one or more PARP inhibitors, e.g., olaparib, rucaparib, niraparib, talazoparib, or any combination thereof) (administered together or sequentially).

[0110] In one aspect, the invention relates to a method of treating a solid cancer in a subject (e.g., a human subject in need thereof), the method comprising administering to the subject a combination of a compound of formula (A) or a pharmaceutically acceptable salt thereof and a compound of formula (M) or a pharmaceutically acceptable salt thereof, in combination with one or more cytostatic or cytotoxic agents (such as one or more selective estrogen receptor degraders (SERDs), e.g., fulvestrant, brilanestrant, elastrant, or any combination of any of the foregoing) (administered together or sequentially).

[0111] In one aspect, the present invention relates to a method of treating breast cancer in a subject (e.g., a subject in need thereof), the method comprising administering to the subject a combination of a compound of formula (A) or a pharmaceutically acceptable salt thereof and a compound of formula (M) or a pharmaceutically acceptable salt thereof, in combination with one or more anti-cancer treatment combinations (administered together or sequentially).

[0112] In one embodiment, the invention relates to a method of treating breast cancer in a subject (e.g., a human subject in need thereof), the method comprising administering to the subject a combination of a compound of formula (A) or a pharmaceutically acceptable salt thereof and a compound of formula (M) or a pharmaceutically acceptable salt thereof, in combination with one or more anti-cancer therapies (such as chemotherapy, radiotherapy, biological therapy, bone marrow transplantation or stem cell transplantation alone or in any combination of any of the foregoing) (administered together or sequentially).

[0113] In one embodiment, the invention relates to a method of treating breast cancer in a subject (e.g., a human subject in need thereof), the method comprising administering to the subject a combination of a compound of formula (A) or a pharmaceutically acceptable salt thereof and a compound of formula (M) or a pharmaceutically acceptable salt thereof, in combination with one or more anti-cancer therapies (such as chemotherapeutic agents) (administered together or sequentially), the chemotherapeutic agent selected from, for example, taxol, doxorubicin, daunorubicin, liposomal doxorubicin, epidoxorubicin, idarubicin, valrubicin, carboplatin, carmustine, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lomustine, melphalan, temozolomide, trabectedin, 5-fluorouracil, 6-mercaptopurine, azacytidine, capecitabine, clofarabine, cytarabine, floxuridine, fludarabine, gemcitabine, methotrexate, pemetrexed, pentostatin, pralatrexate, trifluridine, tipiracil, and any combination of any of the foregoing.

[0114] In another aspect, the present invention relates to a method of inhibiting PI3Kδ and γ and SIK3 in a subject (e.g., a human subject in need thereof), the method comprising administering to the subject an effective amount of a dual selective PI3Kδ and γ (PI3Kδ / γ) inhibitor (e.g., a compound of formula (A) or a pharmaceutically acceptable salt thereof), in combination with a salt-inducible kinase 3 (SIK3) inhibitor (e.g., a compound of formula (M) or a pharmaceutically acceptable salt thereof) (alone or together). In one embodiment, the subject suffers from a solid tumor. In another embodiment, administration is oral administration.

[0115] In another aspect, the present invention relates to a method of inhibiting PI3K, particularly PI3Kδ and γ kinases and SIK3 in a subject (e.g., a subject in need thereof), the method comprising administering to the subject an effective amount of a dual selective PI3Kδ and γ (PI3Kδ / γ) inhibitor (e.g., a compound of formula (A) or a pharmaceutically acceptable salt thereof), in combination with a salt-inducible kinase 3 (SIK3) inhibitor (e.g., a compound of formula (M) or a pharmaceutically acceptable salt thereof) (alone or together). In one embodiment, the subject suffers from a solid tumor. In another embodiment, administration is oral administration.

[0116] In another aspect, the present invention relates to a pharmaceutical composition for treating breast cancer, comprising a compound of formula (A) or a pharmaceutically acceptable salt thereof and a compound of formula (M) or a pharmaceutically acceptable salt thereof. BRIEF DESCRIPTION OF THE DRAWINGS

[0117] Figure 1A and Figure 1BShown is the inhibition of cell growth in the ZR.75.1 breast cancer cell line by (i) fulvestrant (5 μM or 10 μM), (ii) a combination of Compound A and Compound M (3 μM, 5 μM, or 10 μM), and (iii) a combination of fulvestrant (5 μM or 10 μM) with Compound A and Compound M (3 μM, 5 μM, or 10 μM) in the absence of β-estradiol.

[0118] Figure 1C Shown is the cell cycle (including G0 / G1 cell cycle arrest) in ZR.75.1 cells when treated with (i) DMSO, (ii) a combination of Compound A and Compound M (3 μM or 10 μM), (iii) Fulvestrant (3 μM or 10 μM), and (iv) a combination of Fulvestrant (3 μM or 10 μM) with Compound A and Compound M (3 μM or 10 μM) in the absence of β-estradiol.

[0119] Figure 2A and Figure 2B Inhibition of cell growth in the ZR.75.1 breast cancer cell line in the presence of estrogen is shown by (i) fulvestrant (3 μM or 10 μM), (ii) a combination of Compound A and Compound M (3 μM, 5 μM, or 10 μM), and (iii) a combination of fulvestrant (3 μM or 10 μM) with Compound A and Compound M (3 μM, 5 μM, or 10 μM).

[0120] Figure 2C Shown is the cell cycle (including G0 / G1 cell cycle arrest) in ZR.75.1 cells when treated with (i) DMSO, (ii) a combination of Compound A and Compound M (3 μM or 5 μM), (iii) Fulvestrant (1 μM or 3 μM), and (iv) a combination of Fulvestrant (1 μM or 3 μM) with Compound A and Compound M (3 μM or 5 μM) in the presence of β-estradiol.

[0121] Figure 3A and Figure 3B Shown is the inhibition of cell growth in the MCF-7 breast cancer cell line in the presence of β-estradiol by (i) fulvestrant (3 μM or 5 μM), (ii) a combination of Compound A and Compound M (3 μM, 5 μM, or 10 μM), and (iii) a combination of fulvestrant (3 μM) with Compound A and Compound M (3 μM, 5 μM, or 10 μM).

[0122] Figure 4A and Figure 4CShown is the inhibition of cell growth in MCF-7 and MDA-MB-231 breast cancer cell lines by (i) Compound M (5 μM), (ii) Compound A (5 μM), (iii) Taxol (3 nM), and (iv) the combination of Compound M (5 μM), Compound A (5 μM), and Taxol (3 nM).

[0123] Figure 4B Shown is the inhibition of cell growth in the MCF-7 breast cancer cell line by (i) Compound M (5 μM), (ii) Compound A (5 μM), (iii) Doxorubicin (50 nM), and (iv) the combination of Compound M (5 μM), Compound A (5 μM), and Doxorubicin (50 nM).

[0124] Figure 5 Shown is the inhibition of cell growth in the MCF-7 breast cancer cell line due to (i) Compound M (1 μM), (ii) Olaparib (5 μM), and (iii) the combination of Compound M (1 μM) and Olaparib (5 μM).

[0125] Fig. 6A Shown are the inhibition of cell growth in the OVCAR-3 ovarian cancer cell line due to (i) Compound M (5 μM), (ii) Talazoparib (0.1 μM), and (iii) the combination of Compound M (5 μM) and Talazoparib (0.1 μM).

[0126] Figure 6B Shown are the inhibition of cell growth in the SK-OV-3 ovarian cancer cell line due to (i) Compound M (5 μM), (ii) Talazoparib (3 μM), and (iii) the combination of Compound M (5 μM) and Talazoparib (3 μM).

[0127] Figure 6C Shown are the inhibition of cell growth in the OVCAR-3 ovarian cancer cell line due to (i) Compound M (5 μM), (ii) Olaparib (3 μM), and (iii) the combination of Compound M (5 μM) and Olaparib (3 μM).

[0128] Figure 7 Shown is the inhibition of cell growth in the SK-OV-3 ovarian cancer cell line by (i) DMSO, (ii) Compound M (3 μM), (ii) Taxol (6 nM), and (iii) the combination of Compound M (3 μM) and Taxol (6 nM).

[0129] Fig. 8A and Figure 8BInhibition of cell growth in PANC-1 and MIA paca-2 pancreatic cancer cell lines due to a combination of 1 μM, 3 μM or 10 μM of the compound of formula (M) and the compound of formula (A) at a 1:1 ratio (1 μM) is shown.

[0130] Fig. 9 Shown are the tumor volume distributions at day 22 in the MC38 syngeneic murine colon cancer C57BL / 6 model treated with (i) vehicle, (ii) anti-PD-1 antibody (clone RMP1-14), (iii) tenalicept, or (iv) a combination of anti-PD-1 RMP1-14 antibody and tenalicept. DETAILED DESCRIPTION

[0131] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood in the field to which the subject matter belongs. In the event that there are multiple definitions for a term in this article, those in this section shall prevail. Where a URL or other such identifier or address is referenced, it should be understood that such identifiers typically change and specific information on the Internet is constantly changing, but equivalent information can be found by searching the Internet. Reference to this proves the availability and public dissemination of such information.

[0132] It should be understood that the foregoing general description and the following detailed description are exemplary and explanatory only, and are not intended to limit any subject matter. In this application, unless otherwise specifically stated, the use of the singular includes the plural. It must be noted that, as used in the specification, the singular forms "a", "a kind of" and "the" include multiple referents unless the context clearly dictates otherwise. In this application, the use of "or" means "and / or" unless otherwise stated. In addition, the use of the term "include" and other forms such as "comprise", "contain" and "have" is not restrictive.

[0133] Definitions of standard chemical and molecular biology terms can be found in reference works, including but not limited to Carey and Sundberg "ADVANCED ORGANIC CHEMISTRY 4th Edition" Volumes A (2000) and B (2001), Plenum Press, New York, and "MOLECULAR BIOLOGY OF THE CELL 5th Edition" (2007), Garland Science, New York. Unless otherwise indicated, conventional methods of mass spectroscopy, nuclear magnetic resonance (NMR), high pressure liquid chromatography (HPLC), protein chemistry, biochemistry, recombinant DNA techniques, and pharmacology are contemplated to be within the scope of the embodiments disclosed herein.

[0134] Unless specific definition is provided, the nomenclature used in combination with analytical chemistry and medicinal chemistry as described herein and the laboratory processes and techniques of analytical chemistry and medicinal chemistry as described herein are those commonly used. In some embodiments, standard techniques are used for chemical analysis, drug preparation, preparation and delivery and the treatment of patients. In other embodiments, standard techniques are used for recombinant DNA, oligonucleotide synthesis and tissue culture and transformation (e.g., electroporation, liposome transfection). In certain embodiments, for example, reactions and purification techniques are performed using a manufacturer's standardized test kit or as described herein. The above techniques and processes are usually performed by conventional methods, and are performed as described in various general and more specific references cited and discussed throughout this specification.

[0135] The term "acceptable" with respect to a formulation, composition or ingredient, as used herein, means having no persistent detrimental effect on the general health of the subject being treated.

[0136] As used herein, the term "pharmaceutically acceptable" refers to a substance, such as a carrier or diluent or a salt of a compound, which does not abrogate the biological activity or properties of the compound and is relatively non-toxic, i.e., the substance can be administered to a subject without causing undesirable biological effects or interacting in a deleterious manner with any component of the composition in which it is contained.

[0137] Pharmaceutically acceptable salts forming part of the present invention include, but are not limited to, for example, salts derived from inorganic bases such as Li, Na, K, Ca, Mg, Fe, Cu, Zn and Mn; salts of organic bases such as N,N'-diacetylethylenediamine, glucosamine, triethylamine, choline, hydroxide, dicyclohexylamine, metformin, benzylamine, trialkylamines, thiamine and the like; chiral bases, such as alkylphenylamines, glycinol and phenylglycinol, salts of natural amino acids such as glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxyproline, histidine, ornithine, lysine, arginine and serine; quaternary ammonium salts of the compounds of the present invention with alkyl halides and alkyl sulfates such as MeI and (Me)2SO4, non-natural amino acids such as D-isomers or substituted amino acids; and substituted guanidines wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl, ammonium or substituted ammonium salts and aluminum salts. Salts may include acid addition salts where appropriate, which are sulfates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, fumarates, succinates, palmitates, methanesulfonates, benzoates, salicylates, benzenesulfonates, ascorbates, glycerophosphates and ketoglutarates. Pharmaceutically acceptable solvates may be hydrates or include other crystallization solvents such as alcohols.

[0138] The term "pharmaceutical composition" as used herein refers to a mixture of a compound according to any embodiment described herein (such as Compound (A) or a pharmaceutically acceptable salt thereof, Compound (M) or a pharmaceutically acceptable salt thereof, or any combination of any of the foregoing) and one or more additional chemical components (such as, for example, carriers, stabilizers, diluents, dispersants, suspending agents, thickening agents and / or excipients).

[0139] The compounds according to any embodiment described herein (such as Compound (A) or a pharmaceutically acceptable salt thereof, Compound (M) or a pharmaceutically acceptable salt thereof) and pharmaceutical compositions can be administered by various routes of administration, including but not limited to oral and parenteral administration.

[0140] The terms "effective amount" and "therapeutically effective amount" as used herein refer to a sufficient amount of an administered agent or compound that will alleviate to some extent one or more symptoms of the disease or condition being treated. The result is a reduction and / or alleviation of the signs, symptoms or causes of the disease, or any other desired biological system changes. For example, an "effective amount" for therapeutic use is the amount of a compound according to any embodiment described herein required to provide a clinically significant reduction in disease symptoms. In some embodiments, techniques such as dose escalation studies are used to determine the appropriate "effective" amount in any individual case.

[0141] As used herein, the terms "enhance" or "enhanced" mean to increase or prolong either the potency or duration of a desired effect. Thus, with respect to enhancing the effect of a therapeutic agent, the term "enhance" refers to the ability to increase or prolong, either in potency or duration, the effect of other therapeutic agents on a system. As used herein, an "enhancing-effective amount" refers to an amount sufficient to enhance the effect of another therapeutic agent on a desired system.

[0142] As used herein, the term "carrier" refers to relatively nontoxic compounds or agents that facilitate the incorporation of a compound into cells or tissues.

[0143] As used herein, the term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes, but is not limited to, any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, one or more suitable diluents, fillers, salts, disintegrants, binders, lubricants, glidants, wetting agents, controlled release matrices, colorants / flavoring agents, carriers, excipients, buffers, stabilizers, solubilizers, and combinations thereof. Unless any conventional media or agents are incompatible with the active ingredient, their use in the therapeutic compositions of the present invention is contemplated. Supplementary active ingredients may also be incorporated into the composition.

[0144] As used herein, the terms "treat" or "improve" are used interchangeably. These terms refer to methods of obtaining beneficial or desired results, including but not limited to therapeutic beneficial effects and / or preventive beneficial effects. The so-called therapeutic beneficial effect means eradication or improvement of the underlying disease being treated. In addition, the therapeutic beneficial effect is achieved by eradicating or improving one or more physiological symptoms associated with the underlying disease so that the improvement is observed in the patient, although the patient may still suffer from the underlying disease. For preventive beneficial effects, the composition can be administered to a patient at risk of developing a particular disease, or to a patient who reports one or more physiological symptoms of a disease, even though a diagnosis of the disease may not have been made.

[0145] The term "subject" or "patient" as used herein encompasses mammals and non-mammals. Examples of mammals include, but are not limited to, any member of the class mammals, such as humans, non-human primates such as chimpanzees and other apes and monkey species; livestock, such as cattle, horses, sheep, goats, and pigs; livestock, such as rabbits, dogs, and cats; laboratory animals, including rodents, such as rats, mice, and guinea pigs. Examples of non-mammals include, but are not limited to, birds, fish, and the like. In one embodiment of any of the methods, uses, and compositions provided herein, the mammal is a human.

[0146] Suitable dual selective PI3Kδ and γ inhibitors include, but are not limited to, those inhibitors whose δ and γ inhibitory activity is at least 50, 80, or 100 times greater than that of the α and β isomers of PI3K. In one embodiment, the dual selective PI3Kδ and γ inhibitor is tenalicept or a pharmaceutically acceptable salt thereof. In another embodiment, the dual selective PI3Kδ and γ inhibitor is duvelisib or a pharmaceutically acceptable salt thereof.

[0147] SIK3 inhibitors are described in US2021 / 0040486, which is hereby incorporated by reference. A preferred SIK3 inhibitor is a compound of formula (M) or a pharmaceutically acceptable salt thereof.

[0148] Treatments and uses

[0149] In any of the methods of treatment and uses described herein, one or more additional active agents may be administered together with the compound of formula (A) or a pharmaceutically acceptable salt thereof. For example, a compound of formula (A) or a pharmaceutically acceptable salt thereof may be administered in combination (together or sequentially) with a known anticancer therapy such as, but not limited to, chemotherapy, radiotherapy, biological therapy, bone marrow transplantation, stem cell transplantation, or any other anticancer therapy, or with one or more cytostatic, cytotoxic, or anticancer agents, or targeted therapies, alone or in combination, such as, but not limited to, for example, DNA-interactive agents such as fludarabine, cisplatin, chlorambucil, bendamustine, or doxorubicin; alkylating agents such as cyclophosphamide; topoisomerase II inhibitors such as etoposide; topoisomerase I inhibitors such as CPT-11 or topotecan; naturally occurring or synthetic tubulin-interactive agents such as taxol, docetaxel, or an epothilone (e.g., ixabepilone); hormonal agents such as tamoxifen; aromatase inhibitors such as anastrozole, letrozole, exemestane, and testolactone; selective estrogen receptor degraders or downregulators (SEDRs); RD), such as fulvestrant, Giredestrant, Amcenestrant, AZD9833, Rintodestrant, LSZ102, LY3484356, Erastran, ZN-c5, D-0502 and SHR9549; thymidylate synthase inhibitors, such as 5-fluorouracil; and antimetabolites, such as methotrexate; other tyrosine kinase inhibitors, such as Iressa and OSI-774; angiogenesis inhibitors; EGF inhibitors; VEGF inhibitors; CDK inhibitors; SRC inhibitors; c-Kit inhibitors; Her1 / 2 inhibitors, checkpoint kinase inhibitors, salt-inducible kinase 3 (SIK3) inhibitors, and monoclonal antibodies to growth factor receptors such as Erbitux (EGF) and Herceptin (Her2); CD20 monoclonal antibodies, such as (HuMax; Intracel), AME-133v (LY2469298, Applied Molecular Evolution (Applied Molecular Evolution)) and other anticancer agents such as Mundesine, Crizotinib, Romidep (Istodax), Belinostat, Pralatrexate (Folotyn), Gemcitabine, Alecetin (MLN8237), Dasatinib (Sprycel), E7777, Lenalidomide (Revlimid), Nelfinavir (Viracept), Panobinostat (LBH-589), Vorinostat (Zolinza), Everolimus (Afinitor), APO866, Carfilzomib (Kyprolis), Moglizumab (KW-0761), or any combination of any of the foregoing.

[0150] In any of the methods of treatment and uses described herein, the compound of formula (A) or a pharmaceutically acceptable salt thereof can be administered with one or more additional active agents, such as Mundesine, Crizotinib, Romidep (Istodax), Belinostat, Pralatrexate (Folotyn), Gemcitabine, Alecetin (MLN8237), Dasatinib (Sprycel), E7777, Lenalidomide (Revlimid), Nelfinavir (VIracept), Panobinostat (LBH-589), Vorinostat (Zolinza), Everolimus (Afinitor), APO866, Brentuximab (Adcetris), Carfilzomib (Kyprolis), Moglizumab (KW-0761), or any combination of any of the foregoing.

[0151] In any of the methods of treatment and uses described herein, one or more additional active agents may be administered with a compound of formula (M) or a pharmaceutically acceptable salt thereof. For example, a compound of formula (M) or a pharmaceutically acceptable salt thereof may be administered in combination (together or sequentially) with a known anticancer therapy such as, but not limited to, chemotherapy, radiotherapy, biotherapy, bone marrow transplantation, stem cell transplantation, or any other anticancer therapy, or with one or more cytostatics, cytotoxics, or anticancer agents, or targeted therapies, alone or in combination, such as, but not limited to, for example, DNA interacting agents such as fludarabine, cisplatin, chlorambucil, bendamustine, or doxorubicin; alkylating agents such as cyclophosphamide; topoisomerase II inhibitors such as etoposide; topoisomerase inhibitors such as cyclophosphamide; enzyme I inhibitors, such as CPT-11 or topotecan; naturally occurring or synthetic tubulin-interacting agents, such as paclitaxel, docetaxel, or epothilones (e.g., ixabepilone); hormonal agents, such as tamoxifen; aromatase inhibitors, such as anastrozole, letrozole, exemestane, and testolactone; selective estrogen receptor degraders or downregulators (SERDs), such as fulvestrant, Giredestrant, Amcenestrant, AZD9833, Rintodestrant, LSZ102, LY3484356, erastran, ZN-c5, D-0502, and SHR9549; thymidine pyrimidinate synthase inhibitors, such as 5-fluorouracil; and antimetabolites, such as methotrexate; other tyrosine kinase inhibitors, such as Iressa and OSI-774; angiogenesis inhibitors; EGF inhibitors; VEGF inhibitors; CDK inhibitors; SRC inhibitors; c-Kit inhibitors; Her1 / 2 inhibitors, checkpoint kinase inhibitors, salt-inducible kinase 3 (SIK3) inhibitors, and monoclonal antibodies against growth factor receptors such as Erbitux (EGF) and Herceptin (Her2); CD20 monoclonal antibodies, such as (HuMax; Intracel), AME-133v (LY2469298, using molecular evolution) and other anticancer agents such as Mundesine, Crizotinib, Romidep (Istodax), Belinostat, Pralatrexate (Folotyn), Gemcitabine, Alecetin (MLN8237), Dasatinib (Sprycel), E7777, Lenalidomide (Revlimid), Nelfinavir (VIracept), Panobinostat (LBH-589), Vorinostat (Zolinza), Everolimus (Afinitor), APO866, Carfilzomib (Kyprolis), Moglizumab (KW-0761), or any combination of any of the foregoing.

[0152] In any of the treatment methods and uses described herein, the compound of formula (M) or a pharmaceutically acceptable salt thereof can be administered with one or more additional active agents, such as Mundesine, Crizotinib, Romitriptyp (Istodax), Belinostat, Pralatrexate (Folotyn), Gemcitabine, Alecetin (MLN8237), Dasatinib (Sprycel), E7777, Lenalidomide (Revlimid), Nelfinavir (VIracept), Panobinostat (LBH-589), Vorinostat (Zolinza), Everolimus (Afinitor), APO866, Brentuximab (Adcetris), Carfilzomib (Kyprolis), Moglizumab (KW-0761), or any combination of any of the foregoing.

[0153] In any of the methods of treatment and uses described herein, a compound of formula (A) or a pharmaceutically acceptable salt thereof or a compound of formula (M) or a pharmaceutically acceptable salt thereof may be administered in combination with radiation therapy.

[0154] In any of the treatment methods and uses described herein, the compound of formula (A) or a pharmaceutically acceptable salt thereof and / or the compound of formula (M) or a pharmaceutically acceptable salt thereof may be administered in combination with surgery (including before, after or during surgery).

[0155] Any of these treatments may be administered simultaneously, separately, sequentially and / or spaced in time.

[0156] Pharmaceutical composition

[0157] The present invention provides a pharmaceutical composition comprising a compound of formula (A) or a pharmaceutically acceptable salt thereof. The pharmaceutical composition may comprise one or more additional active ingredients, as described herein. The pharmaceutical composition may be administered for any disorder described herein.

[0158] In one embodiment, the pharmaceutical composition comprises a therapeutically effective amount of a compound of formula (A) or a pharmaceutically acceptable salt thereof as an active ingredient. If desired, the pharmaceutical composition contains a compound of formula (A) or a pharmaceutically acceptable salt thereof as an active ingredient and one or more pharmaceutically acceptable excipients or carriers, such as inert solid diluents and fillers, diluents (including sterile aqueous solutions and various organic solvents), penetration enhancers, solubilizers and adjuvants, or any combination of any of the foregoing.

[0159] The present invention also provides a pharmaceutical composition comprising a compound of formula (M) or a pharmaceutically acceptable salt thereof. The pharmaceutical composition may comprise one or more additional active ingredients, as described herein. The pharmaceutical composition may be administered for any disorder described herein.

[0160] In another embodiment, the pharmaceutical composition comprises a therapeutically effective amount of a compound of formula (M) or a pharmaceutically acceptable salt thereof as an active ingredient. If desired, the pharmaceutical composition contains a compound of formula (M) or a pharmaceutically acceptable salt thereof as an active ingredient and one or more pharmaceutically acceptable excipients or carriers, such as inert solid diluents and fillers, diluents (including sterile aqueous solutions and various organic solvents), penetration enhancers, solubilizers and adjuvants, or any combination of any of the foregoing.

[0161] The compounds and pharmaceutical compositions described herein can be administered alone or in combination with one or more other agents, which are also typically administered in the form of a pharmaceutical composition. Where necessary, the compounds and compositions described herein and other agents can be mixed into a single preparation or the two components can be formulated into separate preparations to use them in combination individually or simultaneously.

[0162] The methods and uses described herein include administering the inhibitor according to any embodiment described herein alone, or in combination as described herein, and optionally including one or more suitable diluents, fillers, salts, disintegrants, binders, lubricants, glidants, wetting agents, controlled release matrices, colorants / flavoring agents, carriers, excipients, buffers, stabilizers, solubilizers, and combinations thereof in each case. The formulation of various pharmaceutical compositions is known in the art. See, e.g., Anderson, Philip O.; Knoben, James E.; Troutman, William G, eds., Handbook of Clinical Drug Data, 10th ed., McGraw-Hill, 2002; Pratt and Taylor, eds., Principles of Drug Action, 3rd ed., Churchill Livingston, New York, 1990; Katzung, ed., Basic and Clinical Pharmacology, 9th ed., McGraw Hill, 2003; Goodman and Gilman, eds., The Pharmacological Basis of Therapeutics, 10th ed., McGraw Hill, 2001; Remingtons Pharmaceutical Sciences, 20th ed., Lippincott Williams & Wilkins., 2000; Martindale, The Extra Pharmacopoeia, 32nd ed. (The Pharmaceutical Press, London, 1999), all of which are incorporated herein by reference in their entirety.

[0163] The compounds and compositions according to any embodiment described herein can be administered by any route capable of delivering the compound to the site of action, such as oral route, intraduodenal route, parenteral injection (including intravenous, intraarterial, subcutaneous, intramuscular, intravascular, intraperitoneal or infusion), topical administration (e.g., transdermal administration), rectal administration, local delivery by catheter or stent, or by inhalation. The compounds and compositions according to any embodiment described herein can also be administered by intrafatty or intrathecal injection.

[0164] The compositions according to any embodiment described herein can be administered in solid, liquid or dry powder form (such as lyophilized form). The pharmaceutical composition can be packaged in a manner convenient for delivery, including, for example, solid dosage forms such as capsules, sachets, cachets, gelatin, paper, tablets, capsules, suppositories, pills, lozenges, and lozenges. The type of packaging will generally depend on the desired route of administration. Implantable sustained-release formulations are also contemplated, as are transdermal formulations.

[0165] The following general methods described herein provide ways and methods for preparing and using the compounds of the present invention, and are illustrative rather than restrictive. Further modifications and other novel methods of the methods provided may also be designed to achieve and be used for the purposes of the present invention. Therefore, it should be understood that other embodiments may exist that fall within the spirit and scope of the present invention as defined by the attached specification.

[0166] Example

[0167] Example 1

[0168] Composition of the compound of formula (A)

[0169] Tenalisep (compound of formula (A)) is available as tablets in 200 mg and 400 mg strengths. Exemplary compositions comprising tenalisep are shown in Table 1.

[0170] Table 1. Exemplary composition of Tenalis

[0171]

[0172]

[0173] Table 2: Exemplary composition of 200 mg and 400 mg strengths of Tenalis

[0174]

[0175] Manufacturing process:

[0176] 1. Dispense raw material quantities as outlined in the table above.

[0177] 2. API (compound of formula (A)) and microcrystalline cellulose (Avicel PH 102) were co-sieved through a #40 mesh screen.

[0178] 3. Dissolve the weighed amount of hydroxypropyl cellulose (Klucel LF) in purified water under stirring in a stainless steel container to obtain a clear solution.

[0179] 4. The blend from step 2 was granulated with the binder solution from step 3 in a rapid mixer granulator (RMG).

[0180] 5. Dry the wet material from step 4 in a flash dryer at an inlet temperature of 65°C.

[0181] 6. Manually pass the dried granules from step 5 through a #24 mesh screen and grind the oversized granules through a multi-mill equipped with a medium speed 1.0 mm screen and a forward blade. Sieve the ground granules again through a 24# mesh screen.

[0182] 7. Croscarmellose sodium (Ac-di-sol SD 711), colloidal silicon dioxide (Aerosil 200) and talc (purified) were sieved through a #40 mesh screen and mixed with the granules from step 6 in a blender at 12 RPM for 10 minutes.

[0183] 8. Magnesium stearate was screened through #60 mesh and mixed with the blend from step 7 in a blender at 12 RPM for 6 minutes.

[0184] 9. Compact the lubricated blend using a suitable punch.

[0185] 10. Disperse Opadry Yellow 03F520226 in purified water in a stainless steel container with stirring.

[0186] 11. Coat compressed tablets with the Opadry dispersion from step 9 until a 3% weight gain is obtained in a pan coater.

[0187] Example 2

[0188] Pharmacokinetics

[0189] Pharmacokinetic studies after single and repeated dose administration were conducted in mice, rats, dogs, humans, and monkeys. Tenalised plasma concentrations were determined by a validated LC-MS / MS method. The pharmacokinetic profile of tenalised was evaluated after oral and intravenous administration. It was found that tenalised was rapidly absorbed across the tested species, with moderate clearance, and oral bioavailability of >72.4% in rats, >21.6% in mice, and >100.0% in dogs. Tenalised was found to have high protein binding (>96%) in animal as well as human plasma. In in vitro studies using liver microsomes, metabolic stability followed the hierarchical order of rats>humans>dogs>monkeys>mouse.

[0190] distributed

[0191] Protein Binding

[0192] In vitro protein binding studies were conducted using plasma from rats, dogs, monkeys and humans. Across all species, tenalicept was >96% bound to plasma proteins.

[0193] Plasma stability

[0194] In vitro plasma stability studies were conducted using rat, dog, monkey and human plasma. The concentration of tenalicept was measured by LC-MS / MS. Tenalicept was found to be stable in plasma across all species.

[0195] Organizational Distribution

[0196] Tissue distribution of tenalicept following a single oral administration (10 mg / kg body weight) was studied in male Wistar rats. The rank order of Cmax and AUC in Wistar rats was liver>kidney>heart>plasma>thymus>spleen>serum>lung>blood>brain.

[0197] metabolism

[0198] In in vitro studies using liver microsomes, the metabolic stability of tenalicept followed the rank order of rat>human>dog>monkey>mouse (Table 3). Tenalicept (Compound A) and Compound M exhibited >50% metabolic stability in rats, dogs, and humans, and <30% metabolic stability in mouse and monkey liver microsomes.

[0199] Table 3: Summary of metabolic stability across species

[0200]

[0201] Example 3

[0202] PI3Kδ / γ and SIK3 inhibitory activity

[0203] The compound of formula (A) is a dual PI3Kδ / γ inhibitor and a selective SIK3 inhibitor with nanomolar potency against both PI3Kδ / γ isoforms in enzyme, cell, and blood-based assays while maintaining several-fold selectivity over PI3Kα and β. The compound of formula (M) is a dual PI3Kδ / γ inhibitor and a selective SIK3 inhibitor with nanomolar potency against both PI3Kδ / γ isoforms in enzyme, cell, and blood-based assays while maintaining several-fold selectivity over PI3Kα and β. 50 Inhibition of SIK3. A summary of the in vitro enzymatic and cell-based assays is presented in Table 4.

[0204] Table 4. Summary of in vitro enzyme and cell-based assays

[0205]

[0206] Example 4

[0207] Assay 1: Combination of Compound A and Compound M with Fulvestrant in the Zr.75.1 cell line (without β-estradiol)

[0208] process

[0209] Cell proliferation:

[0210] ■ Zr.75.1 cells were plated at a predetermined density in 96-well plates in their Roswell Park Memorial Institute (RPMI-1640) + 10% FBS (without β-estradiol) culture medium.

[0211] ■ Cells were exposed to DMSO alone (control), Compound A + Compound M, Fulvestrant alone, or a combination of Compound A + Compound M and Fulvestrant.

[0212] ■ Incubate cells in the presence of inhibitors for 72 hours.

[0213] ■ MTT reaction was performed to determine cell viability at the end of the treatment period and absorbance was measured at wavelengths of 560 nM and 640 nM.

[0214] ■ % cell growth inhibition was calculated and Tukey analysis was performed using GraphPad Prism to compare treatment groups.

[0215] Cell cycle analysis:

[0216] ■ Zr.75.1 cells were plated at a predetermined density in 6-well plates in their RPMI 1640 + 10% FBS (without β-estradiol) culture medium.

[0217] ■ Cells were exposed to DMSO alone (control), or Compound A + Compound M, Fulvestrant alone, or a combination of Compound A + Compound M and Fulvestrant.

[0218] ■ Incubate cells in the presence of inhibitors for 48 hours.

[0219] ■ At the end of the treatment period, the cells were pelleted and the supernatant discarded.

[0220] ■ Wash the cell pellet with PBS at 250 x g for 5 minutes.

[0221] ■Resuspend the washed pellet in 1X PBS.

[0222] ■ Add the suspension dropwise to 1 mL of ice-cold 70% ethanol and store at -20°C for 3 hours to up to one week.

[0223] ■ On the day of cell cycle analysis, centrifuge the cells at 1200 rpm for 5 minutes and discard the supernatant.

[0224] ■ Wash cells with PBS and centrifuge at 1200 rpm for 5 minutes and discard the supernatant.

[0225] ■ Resuspend the pellet in PBS and add the cell cycle reagent and mix well. Incubate the samples at room temperature in the dark for 30 minutes.

[0226] ■ Obtain samples and analyze them on the MUSE cell analyzer.

[0227] ■ The % positive population was graphed using GraphPad Prism.

[0228] result

[0229] ■ Compound A + Compound M significantly enhanced the activity of fulvestrant (5 μM and 10 μM) in inhibiting cell growth in the ZR.75.1 breast cancer cell line in the absence of estrogen.

[0230] ■ In the absence of estrogen, combination treatment of fulvestrant and Compound A + Compound M induced >14% (2-fold increase) G0 / G1 cell cycle arrest in the ZR.75.1 breast cancer cell line. The results are shown in Figure 1A , Figure 1B and Figure 1C middle.

[0231] Example 5

[0232] Assay 2: Combination of Compound A + Compound M with Fulvestrant (with β-estradiol) in Zr.75.1 cell line

[0233] process:

[0234] Cell proliferation:

[0235] ■ Zr.75.1 cells were plated at a predetermined density in 96-well plates in their RPMI + 10% FBS (without β-estradiol) medium.

[0236] ■ Cells were exposed to DMSO alone (control), Compound A + Compound M, Fulvestrant alone, or a combination of Compound A + Compound M and Fulvestrant.

[0237] ■ Incubate cells in the presence of inhibitors for 96 hours.

[0238] ■ MTT reaction was performed to determine cell viability at the end of the treatment period and absorbance was measured at wavelengths of 560 nM and 640 nM.

[0239] ■ % cell growth inhibition was calculated and Tukey analysis was performed using GraphPad Prism to compare treatment groups.

[0240] Cell cycle analysis:

[0241] ■ Zr.75.1 cells were plated at a predetermined density in 6-well plates in their RPMI + 10% FBS (without β-estradiol) medium.

[0242] ■ Cells were exposed to DMSO alone (control), Compound A + Compound M, Fulvestrant alone, or a combination of Compound A + Compound M and Fulvestrant.

[0243] ■ Incubate cells in the presence of inhibitors for 48 hours.

[0244] ■ At the end of the treatment period, the cells were pelleted and the supernatant discarded.

[0245] ■ Wash the cell pellet with PBS at 250 x g for 5 minutes.

[0246] ■Resuspend the washed pellet in 1X PBS.

[0247] ■ Add the suspension dropwise to 1 mL of ice-cold 70% ethanol and store at -20°C for 3 hours to up to one week.

[0248] ■ On the day of cell cycle analysis, centrifuge the cells at 1200 rpm for 5 minutes and discard the supernatant.

[0249] ■ Wash cells with PBS and centrifuge at 1200 rpm for 5 minutes and discard the supernatant.

[0250] ■ Resuspend the pellet in PBS and add the cell cycle reagent and mix well. Incubate the samples at room temperature in the dark for 30 minutes.

[0251] ■ Obtain samples and analyze them on the MUSE cell analyzer.

[0252] ■ The % positive population was graphed using GraphPad Prism.

[0253] result

[0254] ■ The combination of Compound A + Compound M significantly enhanced the activity of fulvestrant (3 μM and 10 μM) in inhibiting cell growth in the ZR.75.1 breast cancer cell line in the presence of estrogen.

[0255] ■ In the presence of estrogen, combination treatment with fulvestrant (3 μM) and Compound A + Compound M (3 μM) induced ~10% (3-fold increase) G0 / G1 cell cycle arrest in the ZR.75.1 breast cancer cell line. The results are shown in Figure 2A , Figure 2B and Figure 2C middle.

[0256] Example 6

[0257] Assay 3: Combination of Compound A + Compound M with Fulvestrant (with β-estradiol) in MCF-7 cell line

[0258] process

[0259] Cell proliferation:

[0260] ■ MCF-7 cells were plated at a predetermined density in 96-well plates in their Minimum Essential Medium (MEM) + 10% FBS (containing β-estradiol) medium.

[0261] ■ Cells were exposed to DMSO alone (control), Compound A + Compound M, Fulvestrant alone, or a combination of Compound A + Compound M and Fulvestrant.

[0262] ■ Incubate cells in the presence of inhibitors for 96 hours.

[0263] ■ MTT reaction was performed to determine cell viability at the end of the treatment period and absorbance was measured at wavelengths of 560 nM and 640 nM.

[0264] ■ % cell growth inhibition was calculated and Tukey analysis was performed using GraphPad Prism to compare treatment groups.

[0265] Cell cycle analysis:

[0266] ■ MCF-7 cells were plated at a predetermined density in 6-well plates in their MEM + 10% FBS (containing β-estradiol) culture medium.

[0267] ■ Cells were exposed to DMSO alone (control), Compound A + Compound M, Fulvestrant alone, or a combination of Compound A + Compound M and Fulvestrant.

[0268] ■ Incubate cells in the presence of inhibitors for 48 hours.

[0269] ■ At the end of the treatment period, the cells were pelleted and the supernatant discarded.

[0270] ■ Wash the cell pellet with PBS at 250 x g for 5 minutes.

[0271] ■Resuspend the washed pellet in 1X PBS.

[0272] ■ Add the suspension dropwise to 1 mL of ice-cold 70% ethanol and store at -20°C for 3 hours to one week.

[0273] ■ On the day of cell cycle analysis, centrifuge the cells at 1200 rpm for 5 minutes and discard the supernatant.

[0274] ■ Wash cells with PBS 250 x g?? and centrifuge at 1200 rpm for 5 minutes and discard the supernatant.

[0275] ■ Resuspend the pellet in PBS and add cell cycle reagent and mix well.

[0276] The samples were incubated at room temperature in the dark for 30 minutes.

[0277] ■ Obtain samples and analyze them on the MUSE cell analyzer.

[0278] ■ The % positive population was graphed using GraphPad Prism.

[0279] result:

[0280] The combination of Compound A + Compound M significantly enhanced the activity of Fulvestrant (3 μM, 5 μM) in inhibiting cell growth in the MCF-7 breast cancer cell line in the presence of estrogen. The results are shown in Figure 3A and Figure 3B middle.

[0281] Example 7

[0282] Assay 4: Chemotherapy with / without standard of care (SOC) in breast cancer cell lines (MDA-MB-231 and MCF-7) Combination of Compound A + Compound M

[0283] process

[0284] Cell proliferation:

[0285] ■ Breast cancer cells were plated at predetermined density in 96-well plates in their respective complete culture medium.

[0286] ■ Cells were exposed to DMSO alone (control), Compound A alone, Compound M alone, Taxol / doxorubicin alone, or a combination of Compound A + Compound M and Taxol / doxorubicin.

[0287] ■ Incubate cells in the presence of inhibitors for 72 hours.

[0288] ■ MTT reaction was performed to determine cell viability at the end of the treatment period and absorbance was measured at wavelengths of 560 nM and 640 nM.

[0289] ■ % cell growth inhibition was calculated and Tukey analysis was performed using GraphPad Prism to compare treatment groups.

[0290] result:

[0291] Taxol alone showed an antiproliferative effect by inhibiting growth by 34.5% and 28.8% in MDA-MB-231 and MCF-7 breast cancer cell lines, respectively. The combined addition of Compound A and Compound M (5 μM each) enhanced the activity of Taxol in breast cancer cell lines, with growth inhibition percentages of 49.3% and 49.2% in MDA-MB-231 and MCF-7 cell lines, respectively. The combination of Compound A and Compound M enhanced the activity of Taxol in attenuating the growth of breast cancer cell lines.

[0292] Doxorubicin alone or in combination with Compound A and Compound M (5 μM each) showed 42.8% and 58.1% growth inhibition in the MCF-7 breast cancer cell line, respectively, indicating that the combination of Compound A and Compound M enhanced the activity of doxorubicin in this cell line. The results are shown in Figure 4A , Figure 4B and Figure 4C middle.

[0293] Example 8

[0294] Assay 5: Combination of Compound M and Olaparib in Breast Cancer Cell Line (MCF-7 Cell Line)

[0295] process

[0296] Cell proliferation:

[0297] ■ MCF-7 cells were plated at a predetermined density in 96-well plates in MEM + 10% FBS complete medium.

[0298] ■ Cells were exposed to DMSO alone (control), Compound M alone, Olaparib alone, or a combination of Compound M and Olaparib.

[0299] ■ Incubate cells in the presence of inhibitors for 72 hours.

[0300] ■ MTT reaction was performed to determine cell viability at the end of the treatment period and absorbance was measured at wavelengths of 560 nM and 640 nM.

[0301] ■ % cell growth inhibition was calculated and Tukey analysis was performed using GraphPad Prism to compare treatment groups.

[0302] result:

[0303] In the breast cancer MCF-7 cell line, olaparib alone or in combination with compound M (1 μM) showed 43.2% and 53.0% growth inhibition, respectively. The results are shown in Figure 5 middle.

[0304] Example 9

[0305] Antiproliferative activity of compound M in combination with PARP inhibitors in ovarian cancer cell lines

[0306] Single agent talazopanib exhibited antiproliferative effects (inhibiting growth by 40.23% and 50.0% in OVCAR-3 and SK-OV-3 ovarian cancer cell lines, respectively). The addition of compound (M) (5 μM) enhanced the activity of talazopanib in ovarian cancer cell lines, and the percentage of growth inhibition in OVCAR-3 and SK-OV-3 cell lines was 57.8% and 61.6%, respectively. This is shown in Fig. 6A , Figure 6B and Figure 6C middle.

[0307] Olaparib exhibited an antiproliferative effect by inhibiting growth by 29.3% in the OVCAR-3 cell line.

[0308] Example 10

[0309] Activity of compounds of formula (M) alone and in combination with Taxol in ovarian cancer cell lines

[0310] Taxol demonstrated its antiproliferative effect by inhibiting growth by 44.4%, 25.8%, 17.3% and 59.2% in breast cancer cell lines (MDA-MB-231, ZR.75.1 and MCF-7) and ovarian cancer cell line (SK-OV-3), respectively. Addition of compound (M) (3 μM) increased Taxol-induced growth of ovarian cancer cell line (SK-OV-3). This indicates that compound (M) enhances the activity of Taxol. This is shown in Figure 7 middle.

[0311] Embodiment 11

[0312] Combination of a compound of formula (M) with a compound of formula (A) in pancreatic cancer cell lines

[0313] The combination of the compound of formula (M) and the compound of formula (A) at a molar ratio of 1:1 exhibited an antiproliferative effect by inhibiting growth by 44.9%, 51.2% and 70.05% in pancreatic (PANC-1) cancer cell lines and 36.9%, 46.9% and 59.4% in pancreatic (MIApaca-2) cancer cell lines at 1 μm, 3 μm and 10 μm, respectively. This indicates that the combination of the compound of formula (A) and the compound of formula (M) is effective in pancreatic cancer. This is shown in Fig. 8A and Figure 8B middle.

[0314] Example 12

[0315] Evaluation of the efficacy of tenalisib alone and in combination with anti-PD1 in the MC38 syngeneic murine colon cancer C57BL / 6 model

[0316] In the MC38 syngeneic murine colon cancer model in immunocompetent C57BL / 6 female mice, daily tenalicept alone and in combination with anti-PD-1 (clone: ​​RMP1-14) were evaluated for tumor growth inhibition (TGI). Treatment with tenalicept resulted in a 29% TGI (tumor growth inhibition) compared to the control (on day 22). Treatment with the combination (tenalicept + anti-PD-1) resulted in a 63% TGI compared to the control group (P<0.05). This is shown in Fig. 9 middle.

[0317] Embodiment 13

[0318] Effect of Compound A on breast cancer patients

[0319] Experimental Design

[0320] This is a Phase II randomized open-label study designed to evaluate the preliminary efficacy and safety of tenalicept (Compound A) at two dose levels (800 mg BID and 1200 mg BID) in 40 patients with locally advanced or metastatic breast cancer. 20 patients will be recruited in each group in Group 1 (Tenalisep 800 mg BID) and Group 2 (Tenalisep 1200 mg BID). The two groups will run in parallel.

[0321] Main Objectives

[0322] ● To evaluate the antitumor activity of tenalisib in patients with locally advanced or metastatic breast cancer

[0323] Secondary Objectives

[0324] ●Evaluate the safety and tolerability of tenalised.

[0325] Exploratory goals

[0326] ●Changes in serum cytokine / chemokine and tumor tissue gene expression after tenalisef treatment.

[0327] Key Eligibility Criteria

[0328] 1. Provide fully informed consent prior to any specific research procedure.

[0329] 2. When signing the informed consent form, the patient must be ≥18 years old.

[0330] 3. Female patients with histologically and / or cytologically confirmed locally advanced or metastatic breast cancer that has progressed after at least one line of therapy.

[0331] 4. Patients have at least one measurable lesion at baseline according to RECIST version 1.1, which can be accurately assessed by CT scan or MRI and is suitable for repeated assessment at follow-up.

[0332] 5. ECOG performance status is 0 to 2.

[0333] 6. Life expectancy is at least 3 months.

[0334] 7. Evaluate whether bone marrow, liver, and kidney function are normal within 7 (± 2) days before the first dose of study drug according to the following laboratory requirements:

[0335] ●Hemoglobin ≥8.0 g / dL (do not transfuse blood or treat with erythropoietin to maintain or exceed this level).

[0336] Absolute neutrophil count (ANC) ≥1.0 x 109 / L without growth factor support

[0337] ●Platelet count ≥75 x 109 / L.

[0338] ●Total bilirubin ≤1.5 times ULN (or ≤3x ULN if the patient has Gilbert's syndrome).

[0339] ALT and AST ≤ 3x ULN (≤ 5x ULN for patients with liver metastases or liver involvement).

[0340] Patients with creatinine levels above the ULN have a creatinine clearance ≥50 mL / min (calculated using the Cockcroft-Gault formula).

[0341] 8. Female patients of childbearing potential should be willing to use medically acceptable contraceptive methods as defined in Appendix B while participating in this study and within 30 days after the last dose of study drug, and must have a negative serum pregnancy test within 3 days prior to Cycle 1 Day 1 (C1D1).

[0342] 9. Ability to swallow and retain oral medications.

[0343] 10. Willing and able to comply with study requirements. Patient demographics are provided below.

[0344] Patient Demographics

[0345]

[0346] Efficacy data:

[0347]

[0348] Although the invention herein has been described with reference to specific embodiments, it should be understood that these embodiments are merely illustrations of the principles and applications of the invention. Therefore, it should be understood that many modifications may be made to the exemplary embodiments, and other arrangements may be designed without departing from the spirit and scope of the invention as described above. It is intended that the appended claims define the scope of the invention, and thus cover methods and structures within the scope of these claims and their equivalents.

[0349] All publications, patents, and patent applications cited in this application are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

Claims

1. A method for treating a solid tumor in a subject in need thereof, the method comprising administering to the subject an effective amount of (i) a dual selective PI3Kδ and γ (PI3Kδ / γ) inhibitor, (ii) a salt-inducible kinase 3 (SIK3) inhibitor, or (iii) a combination thereof.

2. The method according to claim 1, wherein the dual selective PI3Kδ and γ (PI3Kδ / γ) inhibitor is a compound of formula (A) or a pharmaceutically acceptable salt thereof.

3. The method according to claim 1 or claim 2, wherein the salt-inducible kinase (SIK3) inhibitor is a compound of formula (M) or a pharmaceutically acceptable salt thereof. 4 . The method according to claim 1 , wherein the PI3Kδ / γ inhibitor and / or the SIK3 inhibitor is administered in the form of a pharmaceutical composition.

5. The method according to any one of claims 1 to 4, wherein the solid tumor is selected from the group consisting of carcinoma, sarcoma, hormonal solid cancer, and any combination of any of the foregoing.

6. The method of any one of claims 1 to 5, wherein the solid tumor is selected from pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular carcinoma, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain tumor, bone cancer, soft tissue sarcoma, and any combination of any of the foregoing.

7. The method of any one of claims 1 to 5, wherein the solid tumor is selected from non-small cell lung cancer, small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, breast cancer, or any combination of any of the foregoing.

8. The method of any one of claims 1 to 5, wherein the solid tumor is breast cancer, ovarian cancer, colon cancer, pancreatic cancer, or any combination of any of the foregoing.

9. The method according to any one of claims 1 to 5, wherein the solid tumor is breast cancer.

10. The method of claim 9, wherein the breast cancer is selected from invasive breast cancer, non-invasive breast cancer, phyllodes tumor of the breast, locally advanced or metastatic breast cancer, hormone receptor (HR) positive and HER2 negative breast cancer, hormone receptor (HR) positive and HER2 positive breast cancer, hormone receptor (HR) negative and HER2 positive breast cancer, hormone receptor (HR) negative and HER2 negative breast cancer (triple negative breast cancer), and any combination of any of the foregoing.

11. The method of claim 9, wherein the breast cancer is selected from the group consisting of invasive breast cancer, non-invasive breast cancer, carcinomatous phyllodes tumor of the breast, and any combination of any of the foregoing.

12. The method of claim 9, wherein the breast cancer is selected from locally advanced or metastatic breast cancer.

13. The method of claim 9, wherein the breast cancer is selected from hormone receptor (HR) positive and HER2 negative breast cancer, hormone receptor (HR) positive and HER2 positive breast cancer, hormone receptor (HR) negative and HER2 positive breast cancer, and hormone receptor (HR) negative and HER2 negative breast cancer, any combination of any of the foregoing.

14. The method of claim 9, wherein the breast cancer is hormone receptor (HR) positive and HER2 negative breast cancer.

15. The method of claim 9, wherein the breast cancer is triple negative breast cancer (TNBC).

16. A method of treating a solid tumor in a subject in need thereof, the method comprising administering to the subject an effective amount of (i) a dual selective PI3Kδ and γ (PI3Kδ / γ) inhibitor, (ii) a salt-inducible kinase 3 (SIK3) inhibitor, (iii) a combination of (i) and (ii), or (iv) a pharmaceutical composition comprising (i), (ii) or (iii).

17. The method according to any one of claims 1 to 16, wherein the PI3Kδ / γ inhibitor is (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one (a compound of formula (A)) or a pharmaceutically acceptable salt thereof, the SIK3 inhibitor is (S)-3-(3-fluorophenyl)-2-(1-((8-hydroxy-9H-purin-6-yl)amino)propyl)-4H-chromen-4-one (a compound of formula (M)) or a pharmaceutically acceptable salt thereof, and (i) the PI3Kδ / γ inhibitor, (ii) the SIK3 inhibitor, (iii) a combination of (i) and (ii), or (iv) a pharmaceutical composition comprising (ii), (ii) or (iii) is administered to the subject by an oral route, an intravenous injection route, an intramuscular injection route, or an intraperitoneal injection route.

18. The method of claim 17, wherein (i) a compound of formula (A) or a pharmaceutically acceptable salt thereof, (ii) a compound of formula (M) or a pharmaceutically acceptable salt thereof, (iii) a combination of (i) and (ii), or (iv) a pharmaceutical composition comprising (i), (ii) or (iii) is administered to the subject via the oral route.

19. The method of claim 17 or claim 18, wherein (i) a compound of formula (A) or a pharmaceutically acceptable salt thereof, (ii) a compound of formula (M) or a pharmaceutically acceptable salt thereof, (iii) a combination of (i) and (ii), or (iv) a pharmaceutical composition comprising (i), (ii) or (iii) is administered in solid form.

20. The method of any one of claims 1 to 19, wherein (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one (compound of Formula (A)), or a pharmaceutically acceptable salt thereof, is administered to the subject at a dose of about 25 mg to about 2400 mg, about 25 mg to about 2000 mg, about 25 mg to about 1800 mg, about 25 mg to about 1600 mg, about 25 mg to about 1200 mg, about 25 mg to about 1000 mg, about 25 mg to about 800 mg, about 25 mg to about 600 mg, about 25 mg to about 400 mg, or about 25 mg to 200 mg.

21. The method of any one of claims 1 to 19, wherein (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one (compound of Formula (A)), or a pharmaceutically acceptable salt thereof, is administered to the subject at a dose of about 100 mg to about 2400 mg, about 100 mg to about 2000 mg, about 100 mg to about 1800 mg, about 100 mg to about 1600 mg, about 100 mg to about 1200 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, or about 100 mg to about 200 mg.

22. The method according to any one of claims 1 to 21, wherein (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one (compound of formula (A)) or a pharmaceutically acceptable salt thereof is administered to the subject in a single dose or multiple doses.

23. The method according to any one of claims 1 to 22, wherein (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one (compound of formula (A)) or a pharmaceutically acceptable salt thereof is orally administered once or twice a day.

24. The method of any one of claims 1 to 23, wherein (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one (compound of formula (A)) or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of about 200 mg to about 1200 mg twice daily or about 400 mg to about 800 mg twice daily.

25. The method of any one of claims 1 to 24, wherein the method comprises administering to the subject an effective amount of the dual selective PI3Kδ and γ (PI3Kδ / γ) inhibitor and a salt-inducible kinase 3 (SIK3) inhibitor, and further comprises administering to the subject an anti-cancer therapy, an endocrine therapy, one or more cytostatics, cytotoxic agents, or anti-cancer agents, or any combination of any of the foregoing.

26. The method of claim 25, wherein the method comprises administering to the subject an effective amount of the dual selective PI3Kδ and γ (PI3Kδ / γ) inhibitor and a salt-inducible kinase 3 (SIK3) inhibitor, wherein the dual selective PI3Kδ and γ (PI3Kδ / γ) inhibitor and the SIK3 inhibitor are administered simultaneously or sequentially.

27. The method according to claim 25 or 26, wherein the anti-cancer treatment is selected from chemotherapy, radiotherapy, biological therapy, bone marrow transplantation, stem cell transplantation or any other anti-cancer therapy, or one or more cytostatic, cytotoxic or anti-cancer agents or targeted therapies, such as DNA interacting agents, such as fludarabine, cisplatin, chlorambucil, bendamustine or doxorubicin, alkylating agents, such as cyclophosphamide, topoisomerase II inhibitors, such as etoposide, topoisomerase I inhibitors, such as CPT-11 or topotecan, naturally occurring or synthetic tubulin interacting agents, such as such as Taxol, docetaxel, or an epothilone (e.g., ixabepilone); hormonal agents such as tamoxifen; aromatase inhibitors such as anastrozole, letrozole, exemestane, and testolactone; selective estrogen receptor degraders or downregulators (SERDs) such as fulvestrant, Giredestrant, Amcenestrant, AZD9833, Rintodestrant, LSZ102, LY3484356, Erastrant, ZN-c5, D-0502, and SHR9549; thymidylate synthase inhibitors such as 5-fluorouracil; and antimetabolites such as methotrexate; other tyrosine kinase inhibitors such as Iressa and OSI-774; angiogenesis inhibitors; EGF inhibitors; VEGF inhibitors; CDK inhibitors; SRC inhibitors; c-Kit inhibitors; Her1 / 2 inhibitors, checkpoint kinase inhibitors, salt-inducible kinase 3 (SIK3) inhibitors, and monoclonal antibodies against growth factor receptors such as Erbitux (EGF) and Herceptin (Her2); CD20 monoclonal antibodies such as (HuMax; Intracel), AME-133v (LY2469298, Applied Molecular Evolution) and other anticancer agents, Such as Mundesine, Crizotinib, Romidep (Istodax), Belinostat, Pralatrexate (Folotyn), Gemcitabine, Alecetin (MLN8237), Dasatinib (Sprycel), E7777, Lenalidomide (Revlimid), Nelfinavir (VIracept), Panobinostat (LBH-589), Vorinostat (Zolinza), Everolimus (Afinitor), APO866, Carfilzomib (Kyprolis), Moglizumab (KW-0761), and any combination of any of the foregoing.

28. The method of any one of claims 1 to 27, wherein the subject is refractory to chemotherapy treatment, or is in relapse following treatment with chemotherapy.

29. The method of claim 25 or claim 26 comprising administering a combination comprising: one or more anti-cancer agents, cytostatic agents, cytotoxic agents, or any combination thereof.

30. The method of claim 29, wherein the one or more anticancer agents, cytostatic agents or cytotoxic agents are selected from PARP inhibitors, CDK inhibitors, MEK inhibitors, B-RAF inhibitors, m-TOR inhibitors, selective estrogen receptor degraders (SERDs), HER-2 or EGFR inhibitors or dual inhibitors, PD1 inhibitors, RET inhibitors or any combination of any of the foregoing.

31. The method of claim 29 or claim 30, wherein the one or more anti-cancer agents are PARP inhibitors.

32. The method of claim 31 , wherein the PARP inhibitor is olaparib or talazoparib.

33. The method of claim 29 or claim 30, wherein the anticancer agent is a selective estrogen receptor degrader (SERD).

34. The method of claim 33, wherein the selective estrogen receptor degrader (SERD) is fulvestrant.

35. The method of claim 25 or claim 26, wherein the one or more anti-cancer treatments are selected from chemotherapy, radiation therapy, biological therapy, bone marrow transplantation, stem cell transplantation, or any combination of any of the foregoing.

36. The method of claim 35, wherein the anti-cancer treatment is chemotherapy with one or more chemotherapeutic agents.

37. The method of claim 36, wherein the chemotherapeutic agent is selected from the group consisting of taxol, doxorubicin, daunorubicin, liposomal doxorubicin, epirubicin, idarubicin, valrubicin, carboplatin, carmustine, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lomustine, melphalan, temozolomide, trabectedin, 5-fluorouracil, 6-mercaptopurine, azacytidine, capecitabine, clofarabine, cytarabine, floxuridine, fludarabine, gemcitabine, methotrexate, pemetrexed, pentostatin, pralatrexate, trifluridine, tipiracil, and any combination of any of the foregoing.

38. The method of claim 36 or claim 37, wherein the chemotherapeutic agent is Taxol, doxorubicin, or a combination of any of the foregoing.

39. The method of any one of claims 1 to 38, wherein the subject is a human.